Associated factors of drug–drug interactions of highly active antiretroviral therapy: report from a referral center

Bibliography

• Global Health Observatory (GHO). HIV/AIDS. Available from: http://www.who.int/gho/hiv/en/ [Accessed at 11 July 2014]
   Google Scholar
• HIV and AIDS estimates (2012). Islamic Republic of Iran. Available from: http://www.unaids.org/en/regionscountries/countries/islamicrepublicofiran/ [Accessed 11 July 2014]
   Google Scholar
• Data on the HIV/AIDS response: Antiretroviral therapy coverage - Data by country. Available from: http://apps.who.int/gho/data/node.main.574?lang=en [Accessed 11 July 2014]
   Google Scholar
• Fang CT, Chang YY, Hsu HM, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 2007;100(2):97-105
   PubMed Web of Science ®Google Scholar
• Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007;45(8):1093-101
   PubMed Web of Science ®Google Scholar
• Seden K, Khoo SH, Back D, et al. Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. J Antimicrob Chemother 2013;68(1):1-3
   PubMed Web of Science ®Google Scholar
• Kyenda NLK, Lubbe MS, Serfontein JHP, Truter I. Prevalence of drugdrug interactions of antiretroviral agents in the private health care sector in South Africa. S Afr Med J 2008;98:109-13
   PubMed Web of Science ®Google Scholar
• Köhler GI, Bode-Böger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38(11):504-13
   PubMed Web of Science ®Google Scholar
• Dabaghzadeh F, Khalili H, Dashti-Khavidaki S, et al. Ginger for prevention of antiretroviral-induced nausea and vomiting: a randomized clinical trial. Expert Opin Drug Saf 2014;13(7):859-66
   PubMed Web of Science ®Google Scholar
• Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004;5:489-96
   PubMed Web of Science ®Google Scholar
• World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2014 Available from: http://www.whocc.no/atc_ddd_index/ [Accessed 20 June 2014]
   Google Scholar
• Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600
   PubMed Web of Science ®Google Scholar
• Hadjibabaie M, Badri S, Ataei S, et al. Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol 2013;71(6):1619-27
   PubMed Web of Science ®Google Scholar
• de Maat MM, de Boer A, Koks CH, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 2004;29(2):121-30
   PubMed Web of Science ®Google Scholar
• Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007;27(10):1379-86
   PubMed Web of Science ®Google Scholar
• Marzolini C, Elzi L, Gibbons S, Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010;15:413-23
   PubMed Web of Science ®Google Scholar
• Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010;50(10):1419-21
   PubMed Web of Science ®Google Scholar
• Kigen G, Kimaiyo S, Nyandiko W, USAID-Academic Model for Prevention Treatment of HIV/AIDS. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One 2011;6(2):e16800
   Web of Science ®Google Scholar
• Rajesh R, Vidyasagar S, Varma DM, Nandakumar K. Highly active antiretroviral therapy induced drug-drug interactions in Indian Human Immunodeficiency Virus positive patients J Clin Med Res. 2011;3(5):60-7
   Google Scholar
• Chaitanya Kumar T, Neelkant Reddy P, Biradar SS, et al. Prevalence of drug-drug interactions of antiretroviral agents in Human Immunodeficiency Virus positive patients at a Tertiary Care Hospital. RGUHS J Pharm Sci 2013;3(3):41-8
   Google Scholar
• Oshikoya KA, Oreagba IA, Ogunleye OO, et al. Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases. Ther Clin Risk Manag 2013;9:215-21
   PubMed Web of Science ®Google Scholar
• Armahizer MJ, Kane-Gill SL, Smithburger PL, et al. Comparing drug–drug interaction severity for clinician opinion to propriety databases. ISRN Critical Care 2013; Article ID 347346
   Google Scholar
• Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004;61:380-5
   PubMed Web of Science ®Google Scholar
• Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci 2008;30:367-74
   PubMed Web of Science ®Google Scholar
• Reis AM, Cassiani SH. Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci 2010;32:822-8
   PubMed Web of Science ®Google Scholar
• Sandson N. Drug-drug interactions: the silent epidemic. Psychiatr Serv 2005;56(1):22-4
   PubMed Web of Science ®Google Scholar
• Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep 2010;7(3):152-60
   PubMedGoogle Scholar
• McCance-Katz EF, Gourevitch MN, Arnsten J, et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addictions 2002;11:271-8
   PubMed Web of Science ®Google Scholar
• Arroyo E, Valenzuela B, Portilla J, et al. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol 2007;63(7):669-75
   PubMed Web of Science ®Google Scholar
• Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pac Clin Electrophysiol 1997;20:2810-16
   PubMed Web of Science ®Google Scholar
• Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005;97:1657-61
   PubMed Web of Science ®Google Scholar
• Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365:682-6
   PubMed Web of Science ®Google Scholar
• Falconer M, Molloy D, Ingerhaug J, Barry M. Methadone-induced torsade de pointes in a patient receiving antiretroviral therapy. Ir Med J 2007;100:631-2
   PubMedGoogle Scholar
• Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007;44:e67-8
   PubMed Web of Science ®Google Scholar
• Gallagher DP, Kieran J, Sheehan G, et al. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis 2008;47:e36-8
   Web of Science ®Google Scholar
• John J, Amley X, Bombino G, et al. Torsade de pointes due to methadone use in a patient with HIV and hepatitis C coinfection. Cardiol Res Pract 2010;524764
   PubMedGoogle Scholar
• Dabiesingh DS, Psevdos G, Sharp VL. Atazanavir-associated QT interval prolongation and torsades de points in a patient with liver cirrhosis. Infect Dis Clin Pract 2011;19:226-8
   Google Scholar
• Package Insert. Kaletra (lopinavir/ritonavir), Abbott Laboratories. Available from: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9642 [Accessed 11 July 2014]
   Google Scholar
• Bräu N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004;39(4):989-98
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438-50
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Vogt MW, Hartshorn KL, Furman PA. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9
   PubMed Web of Science ®Google Scholar
• Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. AIDS Res Hum Retroviruses 1998;14(18):1661-7
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005;49(10):3997-4008
   PubMed Web of Science ®Google Scholar
• Aweeka FT, Kang M, Yu JY, AIDS Clinical Trials Group 5092s Study Team. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med 2007;8(5):288-94
   PubMed Web of Science ®Google Scholar
• Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 2005;9(3):248-57
   PubMed Web of Science ®Google Scholar